Clinical trial
Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events
NCT01186146 is registered in ClinicalTrials.gov with Seung-Jung Park as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events
- Lead sponsor
- Seung-Jung Park
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 31, 2010
- Completion date
- October 31, 2013
- Enrollment
- 5,000 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.